Cargando…

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

BACKGROUND: Current protocols for the treatment of ovarian cancer include combination chemotherapy with a platinating agent and a taxane. However, many patients experience relapse of their cancer and the development of drug resistance is not uncommon, making successful second line therapy difficult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armstrong, Stephen R, Narendrula, Rashmi, Guo, Baoqing, Parissenti, Amadeo M, McCallum, Katherine L, Cull, Stephanie, Lannér, Carita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541348/ https://www.ncbi.nlm.nih.gov/pubmed/23194409 http://dx.doi.org/10.1186/1757-2215-5-40

Ejemplares similares

RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines
por: Narendrula, Rashmi, et al.
Publicado: (2016)

Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells
por: Sprowl, Jason A, et al.
Publicado: (2012)

Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells
por: Chewchuk, Simon, et al.
Publicado: (2017)

Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance
por: Edwardson, Derek W., et al.
Publicado: (2017)

RNA disruption is a widespread phenomenon associated with stress-induced cell death in tumour cells
por: Butler, Phillipe, et al.
Publicado: (2023)

Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
por: Edwardson, Derek W., et al.
Publicado: (2015)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

RNA disruption indicates CHOP therapy efficacy in canine lymphoma
por: Parissenti, Amadeo M., et al.
Publicado: (2019)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer
por: Tokunaga, Megumi, et al.
Publicado: (2022)

Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells
por: Guo, Baoqing, et al.
Publicado: (2016)

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells
por: Wang, Harris, et al.
Publicado: (2014)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer
por: Isonishi, Seiji, et al.
Publicado: (2013)

Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma
por: Song, Caiping, et al.
Publicado: (2018)

Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents
por: Wang, Richard C., et al.
Publicado: (2017)

Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization
por: Heibein, Allan D, et al.
Publicado: (2012)

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
por: Trudeau, Maureen Elizabeth, et al.
Publicado: (2015)

Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma
por: Lv, Xing, et al.
Publicado: (2016)

Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
por: Hembruff, Stacey L, et al.
Publicado: (2008)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer
por: Ito, Tomomichi, et al.
Publicado: (2018)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
por: Howell, Sacha J., et al.
Publicado: (2020)

Bile Acids Increase Doxorubicin Sensitivity in ABCC1-expressing Tumour Cells
por: Chewchuk, Simon, et al.
Publicado: (2018)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
por: Chiarion-Sileni, V, et al.
Publicado: (2007)

Analysis of continuous first-line treatment with docetaxel and carboplatin for advanced non-small cell lung cancer
por: AOKI, TAKUYA, et al.
Publicado: (2014)

A case of primary metastatic glassy cell carcinoma of the uterine cervix that responded to combined docetaxel and carboplatin()
por: Ukita, Yuji, et al.
Publicado: (2013)

Docetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapy
por: Chaillou, Thomas, et al.
Publicado: (2017)

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles
por: SORBE, BENGT, et al.
Publicado: (2013)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response
por: Zheng, Xiaobin, et al.
Publicado: (2016)

Docetaxel: an alternative taxane in ovarian cancer
por: Katsumata, N
Publicado: (2003)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer
por: Zhang, Yiping, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9vtruhat43t7bf15erkgc2n3d6